If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-23. Numbers and descriptions here follow the published literature rather than marketing material.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
intrinsically disordered protein (IDP) A protein (or a region or domain within a protein) that lacks any distinct, fixed three-dimensional structure or organization under physiological conditions, instead changing continuously and randomly between multiple transient conformational states rather than folding into any one stable conformation, especially in the absence of specific macromolecular interaction partners. The majority of eukaryotic proteins contain domains with intrinsic structure alongside unstructured domains. Peptide sequences lacking intrinsic order are generally characterized by high proportions of charged and hydrophilic amino acids and low proportions of hydrophobic amino acids, making them inherently flexible, accessible, and modifiable, which allows the same peptide sequence to have distinct functions across a wide variety of biochemical circumstances. They are frequently enriched in binding motifs and are common targets of post-translational modifications, giving them important roles in cell signaling pathways and as hubs in protein complexes.
Nixon and Kissinger played a "good cop-bad cop" routine with Dobrynin, with Nixon acting the part of the petulant president at the end of his patience with North Vietnam, while Kissinger acted as the reasonable diplomat anxious to improve relations with the Soviet Union, saying to Dobrynin in May 1969 that Nixon would "escalate the war" if the Soviet Union "didn't produce a settlement" in Vietnam. At another meeting in 1969, Kissinger warned Dobrynin that "the train has just left the station and is now headed down the track", saying the Soviet Union better start pressuring North Vietnam now before Nixon did something truly reckless and dangerous. The attempt at "linkage" failed as the Soviet Union did not pressure North Vietnam and instead Dobrynin told Kissinger that the Soviets wanted better relations with the United States regardless of the Vietnam War. After the failure of the "linkage" attempt, Nixon became more open to the alternative strategy suggested by the Defense Secretary Melvin Laird who argued that the burden of the war should be shifted to the South Vietnamese, which was initially called "de-Americanization" and which Laird renamed Vietnamization because it sounded better.
=== Australia === The following programs of study have currently been approved by the Dental Board of Australia for the profession of dental prosthetics. On successful completion of the selected courses, individuals are required to register with the Australian Health Practitioner Regulation Agency to practice legally as a dental prosthetist.
=== Advanced planning and techniques === Retrosynthetic analysis is a strategy used to plan complex syntheses by breaking down the target molecule into simpler precursors. Flow chemistry is a continuous reaction method where reactants are pumped through a reactor, allowing precise control over reaction conditions and scalability. This approach has been employed in the large-scale production of pharmaceuticals such as Tamoxifen.
Sources: en.wikipedia.org
== External links == The MEROPS online database for peptidases and their inhibitors: I04.035 Deprecated link archived 2012-12-23 at archive.today HSP47+Heat-Shock+Proteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
== Natural occurrence == Accurate measurements, beginning in the early 1970s, appeared to detect primordial plutonium-244, making it the shortest-lived primordial nuclide. As the age of the Earth is about 56 half-lives of 244Pu, the amount of 244Pu left should be very small; Hoffman et al. estimated its content in the rare-earth mineral bastnasite as c244 = 1.0×10−18 g/g, which corresponded to the content in the Earth crust as low as 3×10−25 g/g (i.e. the total mass of plutonium-244 in Earth's crust is about 9 g). Since 244Pu cannot be easily produced by natural neutron capture in the low neutron activity environment of uranium ores (see below), its presence cannot plausibly be explained by any other means than creation by r-process nucleosynthesis in supernovae or neutron star mergers. However, the detection of primordial 244Pu in 1971 is not confirmed by recent, more sensitive measurements using accelerator mass spectrometry. In a 2012 study, no traces of 244Pu in the samples of bastnasite (taken from the same mine as in the early study) were observed, so only an upper limit on the 244Pu content was obtained: c244 < 1.5×10−19 g/g: 370 (or fewer) atoms per gram of the sample, at least seven times lower than the abundance measured by Hoffman et al. A 2022 study, once again using accelerator mass spectrometry, could not detect 244Pu in Bayan Obo bastnasite, finding an upper limit of < 2.1×10−20 g/g (about seven times lower than the 2012 study). Thus, the 1971 detection cannot have been a signal of primordial 244Pu.
==== Military ==== The war exposed shortages in the US' weapons stockpiles, calling into question years of defense investment after the September 11 attacks. After less than five months of the war, US was already running out of ammunition against a middle-tier adversary. This could limit US ability to deter other adversaries, including Russia and China. Former secretary of defense Leon Panetta described this as a "dangerous moment". The US has no longer the capacity to deter a future conflict in the South China Sea and elsewhere. The United States consumed more than half of its Patriot missiles used to intercept Iranian missiles and drones. The stockpiles limitation has reportedly turned into a key determinant for continuation or expansion of the conflict. As of 5 August 2026, the US had reportedly used roughly 80% of its THAAD missiles in the war. The United States burned through "virtually all" of its PrSM and ATACMS munitions, and "a little less than half" of its global Tomahawk supply, according to a Reuters report on 4 August. On 6 August, Trump and Hegseth clashed at Camp David over "extreme missile shortages", according to Washington Post. Trump claimed he felt misled, while Hegseth put the blame on his deputy, Stephen Feinberg. Trump denied the aforementioned report, and threatened long prison sentences for anyone leaking information about military supplies. As of 14 August, the US had reportedly lost around 25% of their Reaper drones in the war.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.